Core Viewpoint - The company announced that its controlling shareholder and actual controller, Mr. Jiang Wei, has received a notice of investigation from the China Securities Regulatory Commission for suspected insider trading. This investigation pertains to Mr. Jiang Wei personally and does not involve the company's stock or its daily operations, indicating no significant impact on the company's regular business activities [1] Company Summary - The investigation is specifically focused on Mr. Jiang Wei and is not related to the company's stock or daily operations [1] - The company reassures that the investigation will not have a major impact on its daily business operations [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於召開2024年度暨2025年第一季度中英雙語業績說明會的公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年5月6日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執 行董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：68836 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於第二期以集中競價交易方式回購公司A股股份的進展公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年5月6日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執行 董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：688366 证券简 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company reported a total revenue of 621 million yuan in Q1 2025, a decrease of 4.44% year-on-year, with a net profit attributable to the parent company of 90 million yuan, down 7.41% [1]. - The ophthalmology business faced challenges due to price declines from centralized procurement, while the medical aesthetics sector continued to experience weak terminal consumption [2]. - The company is focused on R&D and innovation, with new products steadily advancing, including approvals for new intraocular lenses and the launch of the fourth-generation hyaluronic acid product "Hai Mei Yue Bai" [2]. - The gross profit margin slightly improved to 69.52% in Q1 2025, attributed to an increase in the proportion of high-margin medical aesthetics products [3]. - The company expects revenue growth to reach 3.103 billion yuan in 2025, with net profit projected at 489 million yuan, reflecting a compound annual growth rate of 16.42% from 2024 to 2025 [4][5]. Summary by Sections Financial Performance - In Q1 2025, the company achieved a gross profit margin of 69.52%, with a net profit margin of 14.60% [3]. - The company reported a stable expense ratio of 51.79%, with sales expenses increasing slightly to 31.35% [3]. - The operating cash flow for Q1 2025 was 86 million yuan, indicating healthy cash flow management [3]. Product Development - The company is advancing its product pipeline, including new medical aesthetics products and intraocular lenses, which are expected to enhance market share [2]. - The innovative "Hai Mei Yue Bai" product is anticipated to address long-standing consumer issues related to hyaluronic acid retention [2]. Market Outlook - The report forecasts revenue growth for the company from 3.103 billion yuan in 2025 to 3.934 billion yuan in 2027, with a corresponding increase in net profit [4][5]. - The company is positioned to benefit from a recovery in the ophthalmology sector as product pipelines expand and centralized procurement impacts stabilize [4].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | H 股 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...

2025年4月26日， 昊海生物发布了2024年年报。 # 财报数据 2024年公司实现营业 收入26.98亿元 ，同比 增长1.64% 。归属于母公司股东的净利润为4.20亿元，同比增 长1.04%。整体毛利率为69.88%，同比下降0.63个百分点。 费用变动 现金流 正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 昊海生物科技（股票代码：688366.SH / 06826.HK）成立于2007年1月24日，是一家专注于生物医用材料 研发、生产和销售的高科技生物医药企业。公司总部位于上海，注册资金1.2亿元人民币，主要从事生物材 料、生物制剂、基因工程药品的研发、生产和销售。 昊海生物科技的主营业务涵盖以下领域： 医疗美容与创面护理产品 公司是 国内第一 大手术防粘连剂生产商，2023年市场份额为28.82%，连续十七年稳居市场首位。 玻尿酸产品 ：公司是国内知名玻尿酸生产商之一，自主研发掌握了单相交联、低温二次交联、线性无颗 粒化交联以及有机交联等交联工艺。第一代产品"海薇"、第二代产品"姣兰"和第三代产品"海魅"已获得 市场广泛认可。 表皮修复基因工程制剂 ...

Financial Performance - The company reported total revenue of 619 million yuan for Q1 2025, a decrease of 4.25% year-on-year [1] - The net profit attributable to shareholders was 90.31 million yuan, down 7.41% compared to the same period last year [1] - The gross margin was 69.52%, an increase of 0.44% year-on-year, while the net profit margin decreased to 13.55%, down 5.36% [1] - Total expenses (selling, administrative, and financial) amounted to 272 million yuan, accounting for 43.96% of revenue, an increase of 5.94% year-on-year [1] - Earnings per share (EPS) was 0.39 yuan, a decrease of 7.14% year-on-year [1] Accounts Receivable and Cash Flow - Accounts receivable represented 77.11% of the latest annual net profit, indicating a significant amount of outstanding payments [1] - Operating cash flow per share was 0.37 yuan, down 18.22% year-on-year [1] Business Model and Market Position - The company's return on invested capital (ROIC) was 5.01%, indicating average capital returns [3] - The net profit margin for the previous year was 13.95%, suggesting high added value for products or services [3] - The company relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers [3] Future Expectations - Analysts expect the company's performance in 2025 to reach 505 million yuan, with an average EPS forecast of 2.17 yuan [4] Fund Holdings - The largest fund holding the company’s shares is Tianhong Pension 2035 Three-Year (FOF) A, with 12,400 shares newly entered into the top ten holdings [5] - The fund's current scale is 120 million yuan, with a net value of 1.0282 as of April 23, showing a 0.12% increase from the previous trading day [5] Product Performance - The company anticipates a 65% year-on-year increase in hyaluronic acid product sales in 2024, despite a slowdown in growth due to market conditions [7]

Financial Performance - The company's operating revenue for 2024 reached RMB 2,697,657,908.35, representing a 1.64% increase compared to RMB 2,654,039,068.79 in 2023[22]. - The net profit attributable to shareholders for 2024 was RMB 420,446,906.16, a slight increase of 1.04% from RMB 416,121,340.71 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 379,096,331.64, showing a decrease of 1.12% compared to RMB 383,406,434.26 in 2023[22]. - The net cash flow from operating activities for 2024 was RMB 648,571,330.09, an increase of 2.23% from RMB 634,449,395.83 in 2023[22]. - As of the end of 2024, the net assets attributable to shareholders were RMB 5,575,258,634.87, a decrease of 1.32% from RMB 5,650,064,203.23 at the end of 2023[22]. - The total assets at the end of 2024 amounted to RMB 7,121,392,176.35, reflecting a slight increase of 0.22% from RMB 7,105,496,951.15 at the end of 2023[22]. - The company's gross profit margin for 2024 was 69.89%, slightly down from 70.46% in the previous year[32]. - The company achieved a revenue of 2,529.85 billion yuan in the pharmaceutical manufacturing industry in 2024, ranking 16th among 41 industrial categories, with a profit total of 342.07 billion yuan, a year-on-year decrease of 1.1%[80]. Dividend Distribution - The proposed cash dividend for the 2024 fiscal year is CNY 6.00 per 10 shares, totaling CNY 138,023,048.40 (including tax) based on a total share capital of 233,193,695 shares, after deducting 3,155,281 shares held in the repurchase account[8]. - The total cash dividend for 2024, including interim distributions, amounts to CNY 230,925,296.80, representing 54.92% of the net profit attributable to shareholders of the listed company[8]. - The company plans to submit the profit distribution proposal to the 2024 annual general meeting of shareholders for approval[8]. Research and Development - Research and development expenses for 2024 amounted to CNY 238.93 million, an increase of CNY 18.83 million, or approximately 8.56% year-on-year, representing 8.86% of total revenue[33]. - The company has a dedicated R&D team of 350 members, accounting for 16.23% of total employees, including 25 PhD holders and 107 master's degree holders[161]. - The company is actively pursuing clinical trials for various new products, including pain-reducing cross-linked sodium hyaluronate gel, which is currently in clinical testing[104]. - The company has established a comprehensive R&D management system and innovation incentive mechanism to enhance its technological capabilities[165]. - The company has filed for 56 new patents during the reporting period, with 59 patents granted, bringing the total to 468[98]. Product Development and Innovation - The company launched the world's first organic cross-linked hyaluronic acid product "Hai Mei Yue Bai" in July 2024, and received approval for its ophthalmic sodium hyaluronate eye drops in March 2024[33]. - The company is focusing on the integration of technologies such as stem cells, tissue engineering, and 3D printing to expand the application of biomedical materials in medical fields[86]. - The company is currently developing new products, including hydrophilic continuous vision intraocular lenses and collagen solutions for skin care, with R&D investments starting in 2024[178]. - The company is advancing various projects in the ophthalmology field, with multiple artificial lens products completing clinical trials and receiving regulatory certifications in early 2025[162]. - The company has developed a patented technology for medical chitosan, which has won multiple national awards, highlighting its innovation capabilities[107]. Market Position and Strategy - The company is committed to maintaining compliance with regulatory standards set by the National Medical Products Administration (NMPA)[16]. - Future outlook includes market expansion strategies and potential mergers and acquisitions to enhance competitive positioning[16]. - The company aims to leverage its research capabilities to drive innovation in medical devices and biopharmaceuticals[16]. - The company is focusing on four major therapeutic areas: medical aesthetics, ophthalmology, orthopedics, and adhesion prevention, which are expected to drive future growth[145]. - The company is actively engaged in the development of new products and technologies, focusing on the biomedical sector[192]. Compliance and Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[11]. - The company has not violated decision-making procedures for external guarantees[11]. - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[7]. - The board of directors and supervisory board members confirm the authenticity, accuracy, and completeness of the annual report[4]. - The governance structure is designed to ensure clear responsibilities and effective decision-making processes within the company[197]. Risks and Challenges - The company faces risks related to technological advancements in the biomedical materials field, which could impact its market competitiveness if it fails to adapt[115]. - The company is exposed to operational risks, including potential product quality issues that could lead to recalls and reputational damage[116]. - The company is affected by industry risks due to ongoing reforms in the pharmaceutical and medical device sectors, which may increase compliance costs and reduce product demand[117]. - The company's growth is partially dependent on the overall growth of the biopharmaceutical industry in China, which could slow down due to various factors[118]. - The company has pursued international expansion through acquisitions, which may be impacted by changes in foreign regulations or geopolitical tensions[118].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司第 五屆監事會第二十一次會議決議公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年4月25日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執 行董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：688366 证券简称：昊海生科 公告 ...